Page last updated: 2024-11-13

e-52862

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID44247568
CHEMBL ID2170062
SCHEMBL ID99404
MeSH IDM0579431

Synonyms (38)

Synonym
CHEMBL2170062 ,
bdbm50396352
S6754
HY-18099
s1ra
SCHEMBL99404
4-(2-((5-methyl-1-(naphthalen-2-yl)-1h-pyrazol-3-yl)oxy)ethyl)morpholine
878141-96-9
morpholine, 4-(2-((5-methyl-1-(2-naphthalenyl)-1h-pyrazol-3-yl)oxy)ethyl)-
api-001 ,
unii-zw18dsd1h4
ZW18DSD1H4 ,
4-(2-(5-methyl-1-(naphthalen-2-yl)-1h-pyrazol-3-yloxy) ethyl) morpholine
AKOS026750239
e-52862
mfcd25976945
NCGC00371119-04
FT-0700391
4-[2-[[5-methyl-1-(2-naphthalenyl)-1h-pyrazol-3-yl]oxy]ethyl]-morpholine
4-[2-[[5-methyl-1-(2-naphthalenyl)-1h-pyrazol-3-yl]oxy]ethyl] morpholine
BCP08990
e52862
compound 28 [pmid: 22784008]
Q7388203
sigma 1 receptor antagonist (s1ra)
gtpl10431
mr309
SB17181
4-[2-(5-methyl-1-naphthalen-2-ylpyrazol-3-yl)oxyethyl]morpholine
4-(2-{[5-methyl-1-(naphthalen-2-yl)pyrazol-3-yl]oxy}ethyl)morpholine
MS-25126
BE177449
e 52862 (s1ra)
DTXSID901022521
4-(2-{[5-methyl-1-(naphthalen-2-yl)-1h-pyrazol-3-yl]oxy}ethyl)morpholine
88e ,
4-[2-(5-methyl-1-naphthalen-2-yl-pyrazol-3-yl)oxyethyl]morpholine
AC-35869

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Initial pharmacokinetics evaluation indicated an excellent brain exposure following oral dosing in mice, suggesting that further investigation into the use of alkoxyisoxazoles as σ1 ligands for antinociception is warranted."( Development of Novel Alkoxyisoxazoles as Sigma-1 Receptor Antagonists with Antinociceptive Efficacy.
Gao, ZB; Gunosewoyo, H; Liu, T; Pang, T; Shi, JJ; Shi, M; Sun, H; Tang, J; Xu, YZ; Yang, F; Yu, LF; Zhang, W; Zheng, YM, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (23)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency9.52210.01237.983543.2770AID1645841
GVesicular stomatitis virusPotency21.31740.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency5.35470.00108.379861.1304AID1645840
Interferon betaHomo sapiens (human)Potency21.31740.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency21.31740.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency21.31740.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency21.31740.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Coagulation factor XHomo sapiens (human)IC50 (µMol)10.00000.00030.593710.0000AID701163
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)10.00000.00011.774010.0000AID701131
Cytochrome P450 2E1Homo sapiens (human)IC50 (µMol)10.00000.01401.68726.2000AID701127; AID701131
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)10.00000.00011.753610.0000AID701129; AID701132
Cytochrome P450 2C8Homo sapiens (human)IC50 (µMol)10.00000.00081.88487.9000AID701133; AID701134
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)7.35000.00002.015110.0000AID701128; AID701152
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)10.00000.00002.800510.0000AID701127; AID701134
Cytochrome P450 2B6Homo sapiens (human)IC50 (µMol)10.00000.00113.418610.0000AID701131; AID701132
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)10.00000.00002.398310.0000AID701131; AID701163
Mu-type opioid receptorHomo sapiens (human)Ki10.00000.00000.419710.0000AID1558955; AID1681778; AID1811101
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)4.70000.00011.18738.9125AID701152
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.32800.00030.769310.0000AID701151
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)10.00000.00091.901410.0000AID1200085; AID1681774; AID1701187; AID701158
Sigma intracellular receptor 2Homo sapiens (human)Ki1.00000.00010.83604.6005AID1744236
Sigma intracellular receptor 2Rattus norvegicus (Norway rat)Ki9.30000.00241.10509.3000AID1726850
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)Ki0.00670.00000.338510.0000AID1127303; AID1744232; AID1855411
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.01750.00000.490110.0000AID1200082; AID1415921; AID1415967; AID1558961; AID1594271; AID1681775; AID1701184; AID1726849; AID1744234; AID1744259; AID1811100; AID1846430; AID701162; AID735278
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mu-type opioid receptorHomo sapiens (human)EC50 (µMol)10.00000.00000.32639.4000AID1558957; AID1681777; AID1811102
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (181)

Processvia Protein(s)Taxonomy
proteolysisCoagulation factor XHomo sapiens (human)
blood coagulationCoagulation factor XHomo sapiens (human)
positive regulation of cell migrationCoagulation factor XHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor XHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2E1Homo sapiens (human)
lipid hydroxylationCytochrome P450 2E1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2E1Homo sapiens (human)
steroid metabolic processCytochrome P450 2E1Homo sapiens (human)
response to bacteriumCytochrome P450 2E1Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2E1Homo sapiens (human)
carbon tetrachloride metabolic processCytochrome P450 2E1Homo sapiens (human)
benzene metabolic processCytochrome P450 2E1Homo sapiens (human)
4-nitrophenol metabolic processCytochrome P450 2E1Homo sapiens (human)
halogenated hydrocarbon metabolic processCytochrome P450 2E1Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2E1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2E1Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
lipid hydroxylationCytochrome P450 2C8Homo sapiens (human)
organic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C8Homo sapiens (human)
steroid metabolic processCytochrome P450 2C8Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C8Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C8Homo sapiens (human)
retinol metabolic processCytochrome P450 2C8Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
oxidative demethylationCytochrome P450 2C8Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2B6Homo sapiens (human)
steroid metabolic processCytochrome P450 2B6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2B6Homo sapiens (human)
cellular ketone metabolic processCytochrome P450 2B6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2B6Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of cell growthSigma intracellular receptor 2Homo sapiens (human)
regulation of intracellular lipid transportSigma intracellular receptor 2Homo sapiens (human)
regulation of intracellular cholesterol transportSigma intracellular receptor 2Homo sapiens (human)
cholesterol homeostasisSigma intracellular receptor 2Homo sapiens (human)
positive regulation of wound healingSigma intracellular receptor 2Homo sapiens (human)
positive regulation of lipoprotein transportSigma intracellular receptor 2Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (86)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityCoagulation factor XHomo sapiens (human)
calcium ion bindingCoagulation factor XHomo sapiens (human)
protein bindingCoagulation factor XHomo sapiens (human)
phospholipid bindingCoagulation factor XHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 2E1Homo sapiens (human)
iron ion bindingCytochrome P450 2E1Homo sapiens (human)
oxidoreductase activityCytochrome P450 2E1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 2E1Homo sapiens (human)
4-nitrophenol 2-monooxygenase activityCytochrome P450 2E1Homo sapiens (human)
oxygen bindingCytochrome P450 2E1Homo sapiens (human)
enzyme bindingCytochrome P450 2E1Homo sapiens (human)
heme bindingCytochrome P450 2E1Homo sapiens (human)
Hsp70 protein bindingCytochrome P450 2E1Homo sapiens (human)
Hsp90 protein bindingCytochrome P450 2E1Homo sapiens (human)
aromatase activityCytochrome P450 2E1Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2E1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2E1Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2E1Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C8Homo sapiens (human)
iron ion bindingCytochrome P450 2C8Homo sapiens (human)
protein bindingCytochrome P450 2C8Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C8Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C8Homo sapiens (human)
aromatase activityCytochrome P450 2C8Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
heme bindingCytochrome P450 2C8Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C8Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
monooxygenase activityCytochrome P450 2B6Homo sapiens (human)
iron ion bindingCytochrome P450 2B6Homo sapiens (human)
testosterone 16-alpha-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
heme bindingCytochrome P450 2B6Homo sapiens (human)
testosterone 16-beta-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2B6Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 2B6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2B6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2B6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingSigma intracellular receptor 2Homo sapiens (human)
oxysterol bindingSigma intracellular receptor 2Homo sapiens (human)
cholesterol bindingSigma intracellular receptor 2Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (51)

Processvia Protein(s)Taxonomy
extracellular regionCoagulation factor XHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor XHomo sapiens (human)
Golgi lumenCoagulation factor XHomo sapiens (human)
plasma membraneCoagulation factor XHomo sapiens (human)
external side of plasma membraneCoagulation factor XHomo sapiens (human)
extracellular spaceCoagulation factor XHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
mitochondrial inner membraneCytochrome P450 2E1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2E1Homo sapiens (human)
cytoplasmCytochrome P450 2E1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2E1Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C8Homo sapiens (human)
plasma membraneCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
cytoplasmCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2B6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2B6Homo sapiens (human)
cytoplasmCytochrome P450 2B6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
endoplasmic reticulumSigma intracellular receptor 2Homo sapiens (human)
lysosomeSigma intracellular receptor 2Homo sapiens (human)
endoplasmic reticulumSigma intracellular receptor 2Homo sapiens (human)
rough endoplasmic reticulumSigma intracellular receptor 2Homo sapiens (human)
plasma membraneSigma intracellular receptor 2Homo sapiens (human)
rough endoplasmic reticulum membraneSigma intracellular receptor 2Homo sapiens (human)
nuclear membraneSigma intracellular receptor 2Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (174)

Assay IDTitleYearJournalArticle
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID701158Inhibition of human ERG transfected in HEK293 cell membranes by whole cell patch clamp assay2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1736850Antiallodynic activity against formalin-induced nociceptive behavior in ICR mouse assessed as licking/biting time at 50 mg/kg, sc pre-treated for 30 mins followed by formalin-stimulation and measured up to 15 to 30 mins2020European journal of medicinal chemistry, Apr-01, Volume: 191Piperidine propionamide as a scaffold for potent sigma-1 receptor antagonists and mu opioid receptor agonists for treating neuropathic pain.
AID1846430Displacement of [3H]-(+)-pentazocine from human sigma1 receptor transfected in HEK293 cell membranes assessed as inhibition constant measured after 120 mins by liquid scintillation counting analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Tricyclic Triazoles as σ
AID1846444Half life in wistar rat at 10 mg/kg, po by HPLC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Tricyclic Triazoles as σ
AID1681774Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ
AID701141Cmax in CD1 mouse at 10 mg/kg, po at 0.5 hrs2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID701138Inhibition of CYP2C9 in human liver microsomes2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1701204Clearance in CD1 mouse at 10 mg/kg, po by HPLC-MS/MS analysis relative to liver blood flow2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID1744238Metabolic stability in rat liver microsomes assessed as half-life at 10 uM incubated for 1 hr in presence of NADPH by LC-MS/MS analysis2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Novel Sigma 1 Receptor Antagonists as Potential Therapeutics for Pain Management.
AID1846445AUC (0 to infinity) in wistar rat at 10 mg/kg, po by HPLC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Tricyclic Triazoles as σ
AID1415943Antinociceptive activity in CD1 mouse partial sciatic nerve ligation model assessed as reduction of surgery-induced mechanical hypersensitivity at 64 mg/kg, ip administered on day 11, 12, 13 post surgery and measured 30 mins post last dose by von frey tes2017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID1415949Antinociceptive activity in CD1 mouse partial sciatic nerve ligation model assessed as reduction of thermal hyperalgesia at 64 mg/kg, ip administered on day 11, 12, 13 post surgery and measured 45 mins post last dose by plantar test relative to control2017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID1415950Antinociceptive activity in CD1 mouse partial sciatic nerve ligation model assessed as reduction of thermal hyperalgesia at 16 mg/kg, ip administered on day 11, 12, 13 post surgery and measured 45 mins post last dose by plantar test relative to control2017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID1701202Elimination half life in CD1 mouse at 10 mg/kg, po by HPLC-MS/MS analysis2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID1200088Antinociceptive activity in CD1 mouse assessed as reduction in capsaicin-induced mechanical hypersensitivity measured as latency time to paw withdrawal response to upward pressure at 80 mg/kg, po administered 30 mins prior to capsaicin-challenge measured 2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Synthesis and structure-activity relationship study of a new series of selective σ(1) receptor ligands for the treatment of pain: 4-aminotriazoles.
AID701150Antiallodynic activity in ip dosed CD1 mouse partial sciatic nerve ligation model assessed as inhibition of mechanical allodynia administered 30 mins by von Frey test2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1171705Antinociceptive activity in Kun Ming mouse pain model assessed as reduction in licking and biting time during phase-2 at 80 mg/kg, ip administered 15 mins prior to formalin challenge relative to vehicle-treated control2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
Synthesis and biological evaluation of novel sigma-1 receptor antagonists based on pyrimidine scaffold as agents for treating neuropathic pain.
AID1127308Antinociceptive activity against formalin-induced pain in Kunming mouse assessed as reduction in mean licking and biting time at 80 mg/kg, ip administered 15 mins before fomalin injection measured during second phase of 15 to 45 mins after formalin challe2014European journal of medicinal chemistry, May-22, Volume: 79Synthesis and biological evaluation of a novel sigma-1 receptor antagonist based on 3,4-dihydro-2(1H)-quinolinone scaffold as a potential analgesic.
AID701128Inhibition of human recombinant CYP2D62012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1200089Antinociceptive activity in CD1 mouse sciatic nerve injury-induced neuropathic pain model assessed as reduction in mechanical hypersensitivity measured as hind paw withdrawal response at 80 mg/kg, po treated 30 mins before test by von Frey filament test2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Synthesis and structure-activity relationship study of a new series of selective σ(1) receptor ligands for the treatment of pain: 4-aminotriazoles.
AID1127304Displacement of [3H]-DTG from sigma 2 receptor in Dunkin Hartley guinea pig membrane after 120 mins by liquid scintillation counting analysis in the presence of sigma 1 receptor blocker (-)-SKF-100472014European journal of medicinal chemistry, May-22, Volume: 79Synthesis and biological evaluation of a novel sigma-1 receptor antagonist based on 3,4-dihydro-2(1H)-quinolinone scaffold as a potential analgesic.
AID1127307Antinociceptive activity against formalin-induced pain in Kunming mouse assessed as reduction in mean licking and biting time at 80 mg/kg, ip administered 15 mins before fomalin injection measured during first phase of 0 to 5 mins after formalin challenge2014European journal of medicinal chemistry, May-22, Volume: 79Synthesis and biological evaluation of a novel sigma-1 receptor antagonist based on 3,4-dihydro-2(1H)-quinolinone scaffold as a potential analgesic.
AID1681772Inhibition of human ERG expressed in CHO cells at 10 uM at -80 mV holding potential by whole cell patch clamp assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ
AID1736857Antinociceptive activity in CCI-induced Sprague-Dawley rat model of neuropathic pain assessed as paw withdrawal latency at 50 mg/kg, sc after 15 days2020European journal of medicinal chemistry, Apr-01, Volume: 191Piperidine propionamide as a scaffold for potent sigma-1 receptor antagonists and mu opioid receptor agonists for treating neuropathic pain.
AID1594271Displacement of [3H]-(+)-pentazocine from recombinant human sigma1 receptor expressed in HEK293 cell membranes after 120 mins by microbeta scintillation counting method2019Bioorganic & medicinal chemistry, 05-01, Volume: 27, Issue:9
Discovery of a novel class of potent and selective tetrahydroindazole-based sigma-1 receptor ligands.
AID1726849Displacement of [3H]pentazocine from human sigma 1 receptor expressed in HEK293 cell membrane incubated for 2 hrs by liquid scintillation counting method
AID701156Analgesic activity in CD1 mouse assessed as inhibition of capsaicin-induced mechanical hypersensitivity at 16 mg/kg, ip administered 15 mins prior to capsaicin challenge measured 30 mins post capsaicin challenge2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1415952Antinociceptive activity in CD1 mouse assessed as reduction of capsaicin-induced mechanical hypersensitivity at 16 mg/kg, ip administered 30 mins prior to capsaicin challenge measured for 15 mins relative to control2017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID1558958Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation at 10 uM incubated for 45 mins by HTRF assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID1701207Cmax in Wistar rat at 10 mg/kg, po by HPLC-MS/MS analysis2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID1300354Displacement of [3H]-DTG from Sigma2 receptor in Dunkin Hartley guinea pig brain membrane after 120 mins by liquid scintillation counting analysis in presence of sigma1 blocker (+)-SKF-100472016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Synthesis and Biological Evaluation of Novel σ1 Receptor Ligands for Treating Neuropathic Pain: 6-Hydroxypyridazinones.
AID1415934Antinociceptive activity in formalin-induced nociceptive CD1 mouse model assessed as reduction of licking-biting time in phase 1 at 40 mg/kg, ip administered 30 mins prior to formalin challenge measured for 5 mins relative to control2017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID701129Inhibition of human recombinant CYP3A42012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1701186Displacement of [3H]-DTG from sigma2 receptor in guinea pig brain membranes at 1 uM incubated for 120 mins by liquid scintillation counting method relative to control2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID1701210Clearance in Wistar rat at 10 mg/kg, po by HPLC-MS/MS analysis relative to liver blood flow2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID1415921Displacement of [3H]-(+)-pentazocine from human sigma 1 receptor transfected in HEK293 cells after 120 mins by liquid scintillation counting method2017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID701143AUC in CD1 mouse at 10 mg/kg, po2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1701188Lipophilicity, logP of compound2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID701151Binding affinity to human 5HT2B receptor2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1846439AUC (0 to infinity) in CD-1 mouse at 10 mg/kg, po by HPLC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Tricyclic Triazoles as σ
AID1415935Antinociceptive activity in formalin-induced nociceptive CD1 mouse model assessed as reduction of licking-biting time in phase 2 at 40 mg/kg, ip administered 30 mins prior to formalin challenge measured for 15 to 30 mins relative to control2017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID701145Apparent permeability across human Caco2 cells at 10 uM after 2 hrs2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1701203AUC (0 to infinity) in CD1 mouse at 10 mg/kg, po by HPLC-MS/MS analysis2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID1200094Dissociation constant, pKa of the compound2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Synthesis and structure-activity relationship study of a new series of selective σ(1) receptor ligands for the treatment of pain: 4-aminotriazoles.
AID1846448Oral bioavailability in wistar rat at 10 mg/kg by HPLC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Tricyclic Triazoles as σ
AID1558957Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID1200091Apparent permeability across human Caco2 cells at 10 uM after 2 hrs2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Synthesis and structure-activity relationship study of a new series of selective σ(1) receptor ligands for the treatment of pain: 4-aminotriazoles.
AID1200093Lipophilicity, log P of the compound2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Synthesis and structure-activity relationship study of a new series of selective σ(1) receptor ligands for the treatment of pain: 4-aminotriazoles.
AID1558961Displacement of [3H]-(+)-pentazocine from human sigma-1 receptor expressed in HEK293 membranes incubated for 120 mins by liquid scintillation counting method2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID701146Neurotoxicity in CD1 mouse assessed as motor impairment at 32 to 64 mg/kg, ip measured after 30 to 180 mins by rotarod test2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1846447Volume of distribution in wistar rat at 10 mg/kg, po by HPLC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Tricyclic Triazoles as σ
AID1701211Volume of distribution at steady state in Wistar rat at 10 mg/kg, po by HPLC-MS/MS analysis2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID1811101Displacement of [3H]-DAMGO from human MOR expressed in CHO-K1 cell membranes incubated for 60 mins measured by MicroBeta scintillation counter method2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Propionamide Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID1409608AUC (viral infection %) for SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells).2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1200095Thermodynamic solubility of the compound in phosphate buffer at pH 7.42015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Synthesis and structure-activity relationship study of a new series of selective σ(1) receptor ligands for the treatment of pain: 4-aminotriazoles.
AID1811102Agonist activity at human MOR expressed in CHO-K1 cells assessed as reduction in forskolin-induced cAMP production incubated for 45 mins by by HTRF assay2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Propionamide Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID701153Binding affinity to rat sigma 2 receptor2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1290892Antinociceptive activity in Kun Ming mouse assessed as inhibition of formalin-induced pain response during phase 2 measured as licking and biting time at 80 mg/kg, ip preincubated with compound for 15 mins followed by formalin injection measured after 15 2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Synthesis and biological evaluation of novel 6,7-dihydro-5H-cyclopenta[d]pyrimidine and 5,6,7,8-tetrahydroquinazoline derivatives as sigma-1 (σ1) receptor antagonists for the treatment of pain.
AID1681768Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes at 10 uM incubated for 60 mins by liquid scintillation counting method2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ
AID1415986Analgesic activity in formalin-induced nociception CD-1 mouse model assessed as reduction in time spent in licking or biting formalin injected hind paw at 80 mg/kg, po pretreated for 30 mins followed by formalin stimulation measured up to 5 mins2017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID1744236Displacement of [3H]-DTG from sigma-2 receptor in human Jurkat cell membrane incubated for 1 hr by liquid scintillation counting method2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Novel Sigma 1 Receptor Antagonists as Potential Therapeutics for Pain Management.
AID1701206Oral bioavailability in CD1 mouse at 10 mg/kg by HPLC-MS/MS analysis2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID1701205Volume of distribution at steady state in CD1 mouse at 10 mg/kg, po by HPLC-MS/MS analysis2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID701140Inhibition of CYP2B6 in human liver microsomes2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1681778Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ
AID1127305Selectivity ratio of Ki for sigma 2 receptor in Dunkin Hartley guinea pig membrane to Ki for sigma 1 receptor in Dunkin Hartley guinea pig membrane2014European journal of medicinal chemistry, May-22, Volume: 79Synthesis and biological evaluation of a novel sigma-1 receptor antagonist based on 3,4-dihydro-2(1H)-quinolinone scaffold as a potential analgesic.
AID1855411Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membranes by microbeta scintillation counting method
AID701139Inhibition of CYP2C8 in human liver microsomes2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1855420Ratio Ki for displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membranes in absence of phenytoin to Ki for displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membranes in presence of phenytoin
AID701131Inhibition of human recombinant CYP1A22012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID701130Lipophilicity, log D of the compound by PH-metrivc technique2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID701159Thermodynamic solubility of the compound in phosphate buffer at pH 7.42012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1415988Antinociceptive activity in capsaicin-induced nociception pain CD-1 mouse model assessed as increase in paw withdrawal latency at 80 mg/kg, po pretreated for 30 mins followed by capsaicin challenge measured after 15 mins by von frey filament assay relativ2017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID701164Inhibition of CYP2D6 in human liver microsomes2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1744259Binding affinity to human sigma-1 receptor2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Novel Sigma 1 Receptor Antagonists as Potential Therapeutics for Pain Management.
AID1701199Analgesic activity in orally dosed mouse model of intraplantar capsaicin-induced mechanical hypersensitivity-induced pain assessed as reduction in mechanical hypersensitivity2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID701163Inhibition of human recombinant CYP2C192012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1171704Antinociceptive activity in Kun Ming mouse pain model assessed as reduction in licking and biting time during phase-1 at 80 mg/kg, ip administered 15 mins prior to formalin challenge relative to vehicle-treated control2014Journal of medicinal chemistry, Dec-26, Volume: 57, Issue:24
Synthesis and biological evaluation of novel sigma-1 receptor antagonists based on pyrimidine scaffold as agents for treating neuropathic pain.
AID1846441Volume of distribution in CD-1 mouse at 10 mg/kg, po by HPLC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Tricyclic Triazoles as σ
AID1846442Oral bioavailability in CD-1 mouse at 10 mg/kg by HPLC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Tricyclic Triazoles as σ
AID1701208Elimination half life in Wistar rat at 10 mg/kg, po by HPLC-MS/MS analysis2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID701149Antihyperalgesic activity in ip dosed CD1 mouse partial sciatic nerve ligation model assessed as inhibition of thermal hyperalgesia administered 45 mins by plantar test2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1811100Displacement of [3H]-(+)-pentazocine from human sigma-1 receptor transfected in HEK293 membranes incubated for 120 mins measured by microBeta scintillation counter method2021Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14
Propionamide Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID1415945Antinociceptive activity in CD1 mouse partial sciatic nerve ligation model assessed as reduction of surgery-induced mechanical hypersensitivity at 32 mg/kg, ip administered on day 11, 12, 13 post surgery and measured 30 mins post last dose by von frey tes2017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID1846446Clearance in wistar rat at 10 mg/kg, po by HPLC-MS/MS analysis relative to liver blood flow2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Tricyclic Triazoles as σ
AID1415987Analgesic activity in formalin-induced nociception CD-1 mouse model assessed as reduction in time spent in licking or biting formalin injected hind paw at 80 mg/kg, po pretreated for 30 mins followed by formalin stimulation measured after 15 to 30 mins re2017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID735277Displacement of [3H]-Di-o-tolyguanidine from guinea pig sigma2 receptor after 120 mins by liquid scintillation counting analysis2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Synthesis and biological evaluation of a new series of hexahydro-2H-pyrano[3,2-c]quinolines as novel selective σ1 receptor ligands.
AID1701187Inhibition of human ERG expressed in CHO cells by patch clamp assay2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID701135Inhibition of CYP3A4 in human liver microsomes2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID735278Displacement of [3H]-(+)-pentazocine from human sigma1 receptor transfected in HEK293 cells after 120 mins by liquid scintillation counting analysis2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Synthesis and biological evaluation of a new series of hexahydro-2H-pyrano[3,2-c]quinolines as novel selective σ1 receptor ligands.
AID1290893Antinociceptive activity in Kun Ming mouse assessed as inhibition of formalin-induced pain response during phase 1 measured as licking and biting time at 80 mg/kg, ip preincubated with compound for 15 mins followed by formalin injection measured up to 5 m2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Synthesis and biological evaluation of novel 6,7-dihydro-5H-cyclopenta[d]pyrimidine and 5,6,7,8-tetrahydroquinazoline derivatives as sigma-1 (σ1) receptor antagonists for the treatment of pain.
AID1736855Therapeutic index, ratio of LD50 for toxicity in ICR mouse to ED50 for antiallodynic activity against formalin-induced nociceptive behavior in ICR mouse2020European journal of medicinal chemistry, Apr-01, Volume: 191Piperidine propionamide as a scaffold for potent sigma-1 receptor antagonists and mu opioid receptor agonists for treating neuropathic pain.
AID1701190Thermodynamic solubility in pH 7.4 buffer2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID1415984Analgesic activity in formalin-induced nociception CD-1 mouse model assessed as reduction in time spent in licking or biting formalin injected hind paw at 40 mg/kg, ip pretreated for 30 mins followed by formalin stimulation measured up to 5 mins2017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID1701209AUC (0 to infinity) in Wistar rat at 10 mg/kg, po by HPLC-MS/MS analysis2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID1701200Analgesic activity in orally dosed mouse model of intraplantar PSNL-induced mechanical hypersensitivity-induced pain assessed as reduction in mechanical hypersensitivity at 80 mg/kg, po2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID1726851Selectivity index, ratio of Ki for human sigma1 receptor expressed in HEK293 cell membrane to Ki for sigma2 receptor in SPRD rat liver membrane
AID1846437Cmax in CD-1 mouse at 10 mg/kg, po by HPLC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Tricyclic Triazoles as σ
AID1409611AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay.2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID701155Inhibition of capsaicin-induced mechanical hypersensitivity in CD1 mouse assessed as paw withdrawal latency at 32 mg/kg, ip administered 15 mins prior to capsaicin challenge measured 30 mins post capsaicin challenge2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1759958Antiallodynic activity in CD-1 mouse assessed as analgesia at 40 mg/kg, sc administered 30 mins prior to capsaicin stimulation and measured after 15 mins by von Frey test (Rvb = 97.3 %)
AID1736848Toxicity in sc dosed ICR mouse assessed as mortality after 24 hrs2020European journal of medicinal chemistry, Apr-01, Volume: 191Piperidine propionamide as a scaffold for potent sigma-1 receptor antagonists and mu opioid receptor agonists for treating neuropathic pain.
AID1744240Metabolic stability in human liver microsomes assessed as half-life at 10 uM incubated for 1 hr in presence of NADPH by LC-MS/MS analysis2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Novel Sigma 1 Receptor Antagonists as Potential Therapeutics for Pain Management.
AID1626224Binding affinity to sigma1 receptor form guinea pig brain membrane in presence of phenytoin by FRET assay2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Development of Novel Alkoxyisoxazoles as Sigma-1 Receptor Antagonists with Antinociceptive Efficacy.
AID1300371Toxicity in Kun Ming mouse assessed as reduction in the permanence time on the rotating rod at 80 mg/kg, ig measured after 30 to 120 mins by rotarod test2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Synthesis and Biological Evaluation of Novel σ1 Receptor Ligands for Treating Neuropathic Pain: 6-Hydroxypyridazinones.
AID701161Displacement of [3H]di-o-tolylguanidine from sigma 2 receptor in guinea pig brain membranes after 120 mins by scintillation counter2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID701127Inhibition of human recombinant CYP2E12012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1744233Displacement of [3H]-DTG from sigma-2 receptor in guinea pig brain membrane incubated for 1 hr by liquid scintillation counting method2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Novel Sigma 1 Receptor Antagonists as Potential Therapeutics for Pain Management.
AID701134Inhibition of human recombinant CYP2C92012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID701157Intrinsic clearance in human liver microsomes assessed as per mg of protein at 10 uM2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1415967Displacement of [3H]-(+)-pentazocine from recombinant human sigma1 receptor expressed in HEK293 cell membranes after 120 mins by microbeta scintillation counting method2017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID1558955Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes incubated for 60 mins by liquid scintillation counting method2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID1415990Stability of the compound assessed as drug degradation at pH 22017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID1200090Intrinsic clearance in human liver microsomes assessed as per mg of protein at 10 uM2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Synthesis and structure-activity relationship study of a new series of selective σ(1) receptor ligands for the treatment of pain: 4-aminotriazoles.
AID1415951Antinociceptive activity in CD1 mouse partial sciatic nerve ligation model assessed as reduction of thermal hyperalgesia at 32 mg/kg, ip administered on day 11, 12, 13 post surgery and measured 45 mins post last dose by plantar test relative to control2017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID1701189Thermodynamic solubility in pH 2 buffer2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID1846440Clearance in CD-1 mouse at 10 mg/kg, po by HPLC-MS/MS analysis relative to liver blood flow2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Tricyclic Triazoles as σ
AID1409613Selectivity ratio: ratio of AUC (viral infection %) of SARS-CoV-2 in the Vero E6 cell line compared to AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay.2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1726850Displacement of (+)-[3H]DTG from sigma 2 receptor in SPRD rat liver membrane incubated for 2 hrs by liquid scintillation counting method
AID701137Inhibition of CYP2C19 in human liver microsomes2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID701136Inhibition of CYP2E1 in human liver microsomes2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID701152Antagonist activity at human 5HT2B receptor2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID701165Partition coefficient, log P of the compound by PH-metrivc technique2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1300353Displacement of [3H]-(+)-pentazocine from Sigma1 receptor in Dunkin Hartley guinea pig brain membrane after 180 mins by liquid scintillation counting analysis2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Synthesis and Biological Evaluation of Novel σ1 Receptor Ligands for Treating Neuropathic Pain: 6-Hydroxypyridazinones.
AID1409607IC50 for antiviral activity against SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells).2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1409614Overall antiviral activity against SARS-CoV-2 (isolate France/IDF0372/2020) in the Vero E6 cell line at 48 h based on three assays 1) detection of viral RNA by qRT-PCR (targeting the N-gene), 2) plaque assay using lysate 3 days after addition of compound 2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1744239Intrinsic clearance in rat liver microsomes at 10 uM incubated for 1 hr in presence of NADPH by LC-MS/MS analysis2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Novel Sigma 1 Receptor Antagonists as Potential Therapeutics for Pain Management.
AID1846454Analgesic activity in po dosed capsaicin-induced mechanical hypersensitivity CD-1 mouse model assessed as reduction in mechanical hypersensitivity preincubated for 30 mins followed by capsaicin stimulation and measured after 15 mins2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Tricyclic Triazoles as σ
AID1200092Efflux ratio of apparent permeability from apical to basolateral side over basolateral to apical side in human Caco2 cells at 10 uM after 2 hrs2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Synthesis and structure-activity relationship study of a new series of selective σ(1) receptor ligands for the treatment of pain: 4-aminotriazoles.
AID1415936Antinociceptive activity in formalin-induced nociceptive CD1 mouse model assessed as reduction of licking-biting time in phase 1 at 80 mg/kg, ip administered 30 mins prior to formalin challenge measured for 5 mins relative to control2017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID1200085Inhibition of human ERG expressed in CHO cells at -80 mV holding potential by whole cell patch clamp assay2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Synthesis and structure-activity relationship study of a new series of selective σ(1) receptor ligands for the treatment of pain: 4-aminotriazoles.
AID1415989Antinociceptive activity in partial sciatic nerve ligation CD-1 mouse model of neuropathic pain assessed as reduction in mechanical hypersensitivity at 80 mg/kg, po administered 8 days post partial sciatic nerve injury measured after 30 mins by von frey f2017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID701132Inhibition of human recombinant CYP2B62012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1744234Displacement of [3H]-pentazocine from sigma-1 receptor in human Jurkat cell membrane incubated for 2 hr by liquid scintillation counting method2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Novel Sigma 1 Receptor Antagonists as Potential Therapeutics for Pain Management.
AID1681775Displacement of 3H](+)-pentazocine from human sigma1 receptor expressed in HEK293 cell membranes incubated for 120 mins by liquid scintillation counting method2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ
AID1701183Aqueous solubility of compound2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID1744232Displacement of [3H]-(+)-pentazocine from sigma-1 receptor in guinea pig brain membranes incubated for 1 hr by liquid scintillation counting method2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Novel Sigma 1 Receptor Antagonists as Potential Therapeutics for Pain Management.
AID1415953Antinociceptive activity in CD1 mouse assessed as reduction of capsaicin-induced mechanical hypersensitivity at 32 mg/kg, ip administered 30 mins prior to capsaicin challenge measured for 15 mins relative to control2017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID701142Inhibition of CYP1A2 in human liver microsomes2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1681769Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation at 10 uM incubated for 45 mins by HTRF assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ
AID1415944Antinociceptive activity in CD1 mouse partial sciatic nerve ligation model assessed as reduction of surgery-induced mechanical hypersensitivity at 16 mg/kg, ip administered on day 11, 12, 13 post surgery and measured 30 mins post last dose by von frey tes2017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID1701201Cmax in CD1 mouse at 10 mg/kg, po by HPLC-MS/MS analysis2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID1701185Displacement of [3H]-DTG from sigma2 receptor in guinea pig brain membranes incubated for 120 mins by liquid scintillation counting method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID701133Inhibition of human recombinant CYP2C82012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1846438Half life in CD-1 mouse at 10 mg/kg, po by HPLC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Tricyclic Triazoles as σ
AID701154Ratio of Ki for human sigma1 receptor in absence of phenytoin to Ki for human sigma 1 receptor in presence of phenytoin2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1127303Displacement of [3H]-(+)-pentazocine from sigma 1 receptor in Dunkin Hartley guinea pig membrane after 180 mins by liquid scintillation counting analysis2014European journal of medicinal chemistry, May-22, Volume: 79Synthesis and biological evaluation of a novel sigma-1 receptor antagonist based on 3,4-dihydro-2(1H)-quinolinone scaffold as a potential analgesic.
AID1415991Stability of the compound assessed as drug degradation at pH 7.42017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID1736849Antiallodynic activity against formalin-induced nociceptive behavior in ICR mouse assessed as licking/biting time at 50 mg/kg, sc pre-treated for 30 mins followed by formalin-stimulation and measured up to 5 mins2020European journal of medicinal chemistry, Apr-01, Volume: 191Piperidine propionamide as a scaffold for potent sigma-1 receptor antagonists and mu opioid receptor agonists for treating neuropathic pain.
AID1681777Agonist activity at human MOR expressed in CHOK1 cells assessed as stimulation of cAMP accumulation incubated for 45 mins by HTRF assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ
AID701144Efflux ratio of apparent permeability from apical to basolateral side over basolateral to apical side in human Caco2 cells at 10 uM after 2 hrs2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1200083Displacement of [3H]-DTG from sigma 2 receptor in guinea pig brain membrane after 120 mins by liquid scintillation counting2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Synthesis and structure-activity relationship study of a new series of selective σ(1) receptor ligands for the treatment of pain: 4-aminotriazoles.
AID1409609Cytotoxicity of compound against Vero E6 cells by MTT assay.2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1558956Displacement of [3H]-DAMGO from human MOR expressed in CHOK1 cell membranes at 10 uM incubated for 60 mins by liquid scintillation counting method2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ
AID1701184Displacement of [3H]-(+)-pentazocine from human sigma1 receptor expressed in HEK293 cell membranes incubated for 120 mins by liquid scintillation counting method2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID1701212Oral bioavailability in Wistar rat at 10 mg/kg by HPLC-MS/MS analysis2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
EST64454: a Highly Soluble σ
AID1626225Antinociceptive activity in Kun Ming mouse assessed as reduction in paw licking and flinching time at 80 mg/kg, ip administered 15 mins prior to formalin challenge measured up to 45 mins post formalin dosing relative to vehicle-treated control2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Development of Novel Alkoxyisoxazoles as Sigma-1 Receptor Antagonists with Antinociceptive Efficacy.
AID701162Displacement of [3H](+)pentazocine from human sigma 1 receptor transfected in HEK293 cell membranes after 120 mins by scintillation counter2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1744241Intrinsic clearance in human liver microsomes at 10 uM incubated for 1 hr in presence of NADPH by LC-MS/MS analysis2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Novel Sigma 1 Receptor Antagonists as Potential Therapeutics for Pain Management.
AID1626230Permeability of the compound after 18 hrs by PAMPA assay2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Development of Novel Alkoxyisoxazoles as Sigma-1 Receptor Antagonists with Antinociceptive Efficacy.
AID1846443Cmax in wistar rat at 10 mg/kg, po by HPLC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Tricyclic Triazoles as σ
AID701160Dissociation constant, pKa of the compound2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).
AID1415985Analgesic activity in formalin-induced nociception CD-1 mouse model assessed as reduction in time spent in licking or biting formalin injected hind paw at 40 mg/kg, ip pretreated for 30 mins followed by formalin stimulation measured after 15 to 30 mins re2017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID1200087Antinociceptive activity against formalin-induced pain in CD1 mouse assessed as reduction in mean licking and biting time at 80 mg/kg, po administered 30 mins before fomalin injection measured during second phase of 15 to 30 mins after formalin challenge2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Synthesis and structure-activity relationship study of a new series of selective σ(1) receptor ligands for the treatment of pain: 4-aminotriazoles.
AID1200086Antinociceptive activity against formalin-induced pain in CD1 mouse assessed as reduction in mean licking and biting time at 40 mg/kg, ip administered 30 mins before fomalin injection measured during second phase of 15 to 30 mins after formalin challenge2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Synthesis and structure-activity relationship study of a new series of selective σ(1) receptor ligands for the treatment of pain: 4-aminotriazoles.
AID1415937Antinociceptive activity in formalin-induced nociceptive CD1 mouse model assessed as reduction of licking-biting time in phase 2 at 80 mg/kg, ip administered 30 mins prior to formalin challenge measured for 15 to 30 mins relative to control2017MedChemComm, Jun-01, Volume: 8, Issue:6
Pyrazolo[3,4-
AID1200082Displacement of [3H](+)-pentazocine from human sigma 1 receptor transfected in HEK293 cells after 120 mins by liquid scintillation counting2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
Synthesis and structure-activity relationship study of a new series of selective σ(1) receptor ligands for the treatment of pain: 4-aminotriazoles.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's12 (46.15)24.3611
2020's14 (53.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.87 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]